Stefano Molica

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (9)

Luca Laurenti

Università Cattolica del Sacro Cuore

ITALY

View details

Francesca Romana Mauro

ITALY

View details

Marta COSCIA

Assistant Professor of Hematology

University of Turin

ITALY

View details

PAOLO SPORTOLETTI

Università degli Studi di Napoli Federico II

ITALY

View details

David Allsup

UNITED KINGDOM

View details

Roberto Marasca

Professore Associato

University of Modena and Reggio Emilia

ITALY

View details

Donato Mannina

Head of Hematology Division

Azienda Ospedale Università Padova

ITALY

View details

Gianluca GAIDANO

Professor of Hematology

ITALY

View details

Ilaria DEL GIUDICE

Sapienza University of Rome

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stefano Molica

Research Interests

Explore related searches

Contact this professor

Articles (10)

Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option

Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis

Real‐world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience

Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model

Current perspectives regarding SARS‐CoV‐2 vaccination in chronic lymphocytic leukemia

Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia

mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

Collaborators (9)

Luca Laurenti

Francesca Romana Mauro

Marta COSCIA

PAOLO SPORTOLETTI

David Allsup

Roberto Marasca

Donato Mannina

Gianluca GAIDANO

Ilaria DEL GIUDICE

Make your next move.